Skin Immunity Sample Collection Involving Blisters and Biopsies
NCT03921515 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL
Last updated 2024-12-13
Summary
Background:
The way the body heals and protects itself from getting sick is called the immune response. Some people with weak immune systems get sick often or get rashes and skin infections. Researchers want to find out how the immune system and skin problems are related so they can help these people.
Objective:
To learn about how immune response and skin healing are related to each other.
Eligibility:
People ages 18-65 with hyper IgE syndrome or Job syndrome or people ages 7-65 with chronic granulomatous disease. Healthy volunteers ages 18 65 are also needed.
Design:
Participants will be screened with:
Medical history
Physical exam
Possible urine tests
Participants will have 1 to 3 visits within about a week. Visits will include the following:
Participants will have a wells device strapped to the inside of the forearm. It will suction the skin and pull the top layer away to form 8 blisters. The skin over the blisters and the liquid inside will be collected.
Participants will have up to 4 skin biopsies. A sharp tool will remove a small plug of skin from the forearm.
Participants may have blood and urine tests.
The skin on participants skin will be rubbed with a cotton swab.
Some participants will have an overnight visit. They will have the blister device placed back on the arm. The wells will be lined up over the blister wounds. The wells will be filled with either saline or the participant s blood serum. The device will be covered and left on the arm for up to 24 hours. Doctors will periodically remove some liquid from the wells.
Conditions
- Hyper-Immunoglobulin E. Syndrome (HEIS)
- Chronic Granulomatous Disease (CGD)
Interventions
- OTHER
-
Blister induction
Blister induction involves creating 8 blisters on the forearm and removing the tops of the blisters for primary cell culture derivation. After blister induction, subjects may have an optional overnight admission to assess cell infiltration in response to autologous serum and/or sterile saline solution.
- OTHER
-
Skin Biopsies
The skin biopsies will involve up to 4 biopsies: 2 initial punch biopsies 2 mm in diameter, followed by a punch biopsy 3 (plus or minus 1) and 7 (plus or minus 2) days later using a 3 mm punch to encompass the initial biopsy sites, capturing the tissue at 3 and 7 days of healing.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Ian A Myles, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 7 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-12-09
- Primary Completion
- 2024-12-10
- Completion
- 2024-12-10
Countries
- United States
Study Locations
More Related Trials
-
Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers
NCT03625219 ·Status: COMPLETED ·Phase: NA
-
Identification of Epidermal Signatures in Patients With Atopic Dermatitis
NCT02680405 ·Status: UNKNOWN
-
Study of Autologous Total Immunoglobulin G Therapy for Atopic Dermatitis
NCT02835170 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Characterization of Chronic Hand Eczema
NCT05026554 ·Status: RECRUITING
-
Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis
NCT01545284 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Molecular Diagnosis of Allergic Contact Dermatitis (SMECA).
NCT06124781 ·Status: RECRUITING ·Phase: NA
-
A Sample Collection Study Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits
NCT04668846 ·Status: UNKNOWN
-
Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation
NCT00445029 ·Status: UNKNOWN
-
Efficacy and Safety of Runzao Zhiyang Capsule to Treat Chronic Eczema
NCT02601222 ·Status: UNKNOWN ·Phase: PHASE4
-
Histopathological Comparison Between Superficial Pressure Ulcers and Incontinence-associated Dermatitis
NCT03685929 ·Status: COMPLETED
-
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
NCT04358224 ·Status: COMPLETED ·Phase: PHASE4
-
Innate Immunity and the Allergic Response
NCT01494948 ·Status: COMPLETED ·Phase: NA
-
Register of Autoimmune Bullous Dermatoses
NCT02899923 ·Status: COMPLETED
-
Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen Extracts
NCT02527122 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Dermal Cooling System for Treatment of Common Skin Conditions
NCT05270512 ·Status: COMPLETED ·Phase: NA
-
Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents
NCT01518348 ·Status: WITHDRAWN ·Phase: PHASE3
-
Registry for the Atopic Dermatitis Research Network
NCT01494142 ·Status: COMPLETED
-
Drug Challenges Without Prior Skin Testing
NCT03158831 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study to Explore the Role of Gut Flora in Eczema
NCT04214548 ·Status: WITHDRAWN
-
The Role of Bacterial Toxins in Human Skin Disease
NCT02910791 ·Status: UNKNOWN
-
Phase II Study to Standardize Allergen Extracts: Determination of Biological Activity in HEP Units
NCT01412528 ·Status: TERMINATED ·Phase: PHASE2
-
Autologous Serum Skin Testing in Patients With Atopic Dermatitis Autologous Serum Skin Testing in Patients With Atopic Dermatitis
NCT01238263 ·Status: COMPLETED
-
Internet and Social Media Use in Dermatology Patients
NCT03913598 ·Status: COMPLETED
-
Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
NCT05580042 ·Status: COMPLETED ·Phase: PHASE1
-
Exploring the Influence of Elevated CO2 on Allergic Skin
NCT06244524 ·Status: NOT_YET_RECRUITING ·Phase: NA